1. Introduction {#sec1}
===============

Saposin B (SapB) is an intralysosomal, heat-stable human glycoprotein that functions as a nonenzymatic cofactor in the degradation of *O*-sulfogalactosylceramide (sulfatide) by presenting the lipid to the active site of the enzyme arylsulfatase A (ASA).^[@ref1],[@ref2]^ SapB was the first of four saposins to be discovered and is a product of the post-translational cleavage of prosaposin, along with SapA, SapC, and SapD.^[@ref1]^ All four saposins are nonenzymatic.^[@ref1],[@ref2]^ SapB has been extensively investigated due to its role in the lethal lysosomal storage disease activator-deficient metachromatic leukodystrophy (AD-MLD), the result of a buildup of sulfatides in the lysosome.^[@ref1],[@ref3]^ SapB favors a dimeric structure, has a variable degree of α-helical character across pH ranges (∼53% at ∼lysosomal pH pf 5; ∼68% at pH 7.0), three disulfide bonds, and a hydrophobic binding pocket, consistent with its role in lipid binding.^[@ref1],[@ref2],[@ref4],[@ref5]^

Previous work has almost exclusively focused on SapB interaction with lipids, lipidlike molecules, and ASA. Recently, our group and others have shown that SapB can bind ligands beyond sulfatide. It has been shown that SapB binds coenzyme Q~10~ (CoQ~10~) and serves as a binding and transfer protein for the coenzyme, with \[SapB-CoQ10\]~complex~ being detected in human urine.^[@ref6],[@ref7]^ It has also been shown that SapB binds the lysosomotropic antimalarial drugs atovaquone^[@ref6]^ (ATO) and chloroquine^[@ref5]^ (CQ), as well as the bisretinoid *N*-retinylidene-*N*-retinylethanolamine^[@ref8]^ (A2E), which accumulates in the lysosome of patients with macular degeneration.^[@ref9]−[@ref11]^

The critical importance of SapB as a lysosomal activator and transporter protein and its multiligand binding characteristics beyond sulfatide degradation raise important questions about the driving forces and factors that influence such a wide range of ligand interactions. Herein, we present evidence using fluorescence spectroscopy and computational docking studies, supported by our prior work using isothermal titration calorimetry (ITC)^[@ref5],[@ref6]^ and protein crystallography,^[@ref5]^ that SapB binds a wide variety of ligands with *K*~D~ values ranging from micromolar to nanomolar (see [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"} and [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Furthermore, we demonstrate that a ligand's calculated partition coefficient (*c* Log *P*) can be used to predict binding affinity with SapB and that SapB-ligand binding is driven principally by entropic factors. We hypothesize that deviation from this general binding model, as in the case of the \[SapB-ATO\]~complex~, is likely due to the presence of a second and strong binding site for ATO (and perhaps for other ligands as well) on the surface of the protein. Such superficial binding is shown to block access of other ligands to the deeper binding pocket inside SapB.

![Spectrophotometric titrations of SapB with different ligands. (a) HCQ, (b) ACar, (c) PEth, (d) PCho, (e) CoQ~4~, (f) CoQ~9~. Conditions: 40 μM SapB in 50 mM phosphate buffer, pH 5.5 with 2 μL injections of 2 mM ligand (only HCQ was dissolved in 50 mM phosphate buffer, pH 5.5; all other ligands were prepared in 100% dimethylformamide (DMF)), conducted at room temperature. Because of HCQ's own fluorescence emission of around 360 nm, minimal fluorescence quenching was observed upon HCQ binding to SapB. The data was analyzed using the double logarithmic Stern--Volmer equation, as previously described.^[@ref5],[@ref8]^ SapB was prepared and structurally validated, as previously described.^[@ref12]^](ao-2017-01334z_0004){#fig1}

![Structures of Some SapB Binding Ligands.\
(a) Hydroxychloroquine (HCQ), (b) CQ, (c) ATO, (d) apocarotenal (ACar), (e) A2E, (f) coenzyme Q~4~, Q~9~ (CoQ~4~, CoQ~9~), or CoQ~10~, (g) phosphatidylethanolamine (PEth), and (h) phosphatidylcholine (PCho).](ao-2017-01334z_0005){#sch1}

2. Results and Discussion {#sec2}
=========================

The interaction of SapB, prepared as previously described,^[@ref12]^ with a variety of ligands was followed by monitoring the quenching of the fluorescence intensities of the protein's tyrosine residues^[@ref8]^ upon binding ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a--f). An excitation wavelength of 278 nm was used and the fluorescence emission was monitored between 285 and 500 nm.

For each ligand tested, the quenching of the protein's fluorescence intensity was monitored at the maximum emission wavelength of 330 nm (see [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) and the data was analyzed using double logarithmic Stern--Volmer plots^[@ref5],[@ref8],[@ref13]^ ([Supporting eq 1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01334/suppl_file/ao7b01334_si_001.pdf) and [Supporting Figure 1a--f](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01334/suppl_file/ao7b01334_si_001.pdf)). The log of the binding affinity (*K*~A~) for each ligand is reported in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and shows a general increase in the *K*~A~ value as the ligand hydrophobicity increases, consistent with the known primary function of SapB as a binder and extractor of lipids within the lysosome. Interestingly, a plot of Log *K*~A~ versus *c* Log *P* ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) shows a strong correlation (i.e., *R*^2^ \> 0.9) and a clear linear trend of all ligands tested with the exception of \[SapB-ATO\]~complex~, suggesting that \[SapB-Ligand\]~complex~ formation is primarily driven by entropy. To support this idea, we measured the thermodynamic binding parameters Δ*S*° and Δ*H*° for six of the bound substrates shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"} (see [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). As can be observed, with the exception of ATO, the binding interactions are both enthalpically and entropically favored, although the entropic contributions are much more pronounced (i.e., −20.6 kJ mol^--1^ \< −*T*Δ*S* \< −47.9 kJ mol^--1^ vs −1.8 kJ mol^--1^ \< Δ*H* \< −8.6 kJ mol^--1^) than their enthalpic counterparts. Notably, the strongest entropy of binding observed for ATO, postulated to bind at an alternate "second" binding site, offers further insights into the deviation from the Log *K*~A~ versus *c* Log *P* plot linearity, as mentioned earlier (see [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).

![Plot of Log *K*~A~ against ligands' calculated *c* Log *P* for several ligands binding to SapB at pH 5.5. Each fluorescence quenching experiment was performed in triplicate with each point on the plot representing the average of three runs. The data was fitted using a linear least squares regression, excluding the data point for ATO. The slope and intercept of the best-fit line (*R*^2^ = 0.934) are 0.191 and 3.28, with standard errors of 0.017 and 0.190, respectively. The shaded area denotes the upper and lower 95% confidence intervals.](ao-2017-01334z_0001){#fig2}

###### Log *K*~A~ for the Binding of Several Ligands by SapB and the Log of the Calculated Partition Coefficient (*c* Log *P*)

  ligand                     Log *K*~A~   *c* Log *P*[a](#t1fn1){ref-type="table-fn"}
  -------------------------- ------------ ---------------------------------------------
  hydroxychloroquine         3.809        3.90
  chloroquine                4.620        4.70
  atovaquone                 6.950        5.80
  A2E                        4.680        8.20
  coenzyme Q~4~              5.103        8.72
  apocarotenal               4.618        9.40
  phosphatidylethanolamine   5.227        10.4
  phosphatidylcholine        6.075        12.9
  coenzyme Q~9~              6.196        15.5
  coenzyme Q~10~             7.382        21.0

*c* Log* P* values were obtained using the ACD/Log *P* method.^[@ref14]−[@ref18]^

###### Thermodynamic Parameters for the Binding of Several Ligands by SapB (See Also [Supporting Figure 3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01334/suppl_file/ao7b01334_si_001.pdf))

  ligand    Δ*S*° (J mol^--1^ K^--1^)   Δ*H*° (kJ mol^--1^)   Δ*G*° (kJ mol^--1^)
  --------- --------------------------- --------------------- ---------------------
  ATO       161.01 ± 4.07               8.32 ± 1.24           --39.68 ± 1.74
  CQ        69.27 ± 5.15                --5.68 ± 1.58         --26.34 ± 2.20
  CoQ~4~    112.39 ±4.07                --8.57 ± 1.25         --42.08 ± 1.74
  PEth      95.73 ± 4.65                --6.06 ± 1.41         --34.61 ± 1.89
  PCho      91.32 ± 1.16                --1.87 ± 0.33         --29.10 ± 0.48
  CoQ~10~   95.90 ± 0.66                --1.76 ± 0.17         --30.36 ±0.26

The previously published crystal structures of SapB^[@ref4]^ and \[SapB-CQ\]~complex~^[@ref5]^ show a v-shaped, hydrophobic pocket for SapB suitable for lipid and/or small molecules binding. However, NMR solution structure studies^[@ref19]^ of SapB have proven challenging, with molecular dynamics modeling revealing^[@ref20]^ an inherently flexible SapB dimer, with at least three separate conformations postulated. Additional work has shown that this dimeric flexibility might play a role in overall SapB function because mutants with more rigidity have led to a decline in function.^[@ref4]^ This suggests that a mechanism underlying the broad binding specificity of SapB reported herein, and its ability to bind a variety of hydrophobic molecules, is likely due to the inherent conformational flexibility of the protein.^[@ref19],[@ref20]^

To probe the adaptability of the pocket and its ability to accept multiple ligands, we conducted "order of addition" fluorescence binding experiments using preformed \[SapB-Ligand\]~complexes~, followed by direct titrations of a second ligand (ligand = ATO or A2E; see [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}c, [1](#sch1){ref-type="scheme"}e, respectively). Titration of A2E into a preformed solution of \[SapB-ATO\]~complex~ resulted in no A2E binding compared to SapB binding of A2E alone, as a control ([Supporting Figure 4](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01334/suppl_file/ao7b01334_si_001.pdf), green and black curves, respectively). This lack of A2E binding indicates a blocking effect for ATO consistent with the computational docking studies^[@ref21]−[@ref23]^ shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a, suggesting that ATO is more surface bound than "buried" inside the SapB hydrophobic pocket. However, titration of ATO into a preformed \[SapB-A2E\]~complex~ solution resulted in a clear binding of ATO to SapB (see [Supporting Figure 5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01334/suppl_file/ao7b01334_si_001.pdf)). The inability of the SapB dimer to accommodate two ATO molecules at the same time is due to the surface-bound nature of the ATO molecule and the subsequent asymmetric structure of the SapB dimer ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a). These observations are in agreement with a recent ITC study suggesting one ATO molecule binds per SapB dimer.^[@ref6]^ On the contrary, SapB dimer is able to initially bind one A2E molecule followed by another molecule of ATO ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}b and [Supporting Figure 5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01334/suppl_file/ao7b01334_si_001.pdf)) presumably because A2E binds into a deeper pocket buried inside the hydrophobic cavity of the SapB dimer.

![(a) Computational models of (a) \[SapB-ATO\]~complex~ and (b) \[SapB-ATO-A2E\]~complex~.](ao-2017-01334z_0003){#fig3}

3. Conclusions {#sec3}
==============

In conclusion, we demonstrate that (a) SapB binds a broad range of ligands, (b) such binding is primarily driven by entropic forces, and (c) can be predicted from the log *K*~A~ versus ligand's *c* Log *P* plot, and (d) that SapB can accommodate certain ligands in a specific and sequential order. Such a preferred order of binding is likely due to the large hydrophobic pocket produced upon the homodimerization and conformational flexibility of SapB as previously described.^[@ref20]^

4. Experimental Section {#sec4}
=======================

4.1. Materials and Methods {#sec4.1}
--------------------------

Saposin B (SapB) was prepared and purified according to literature reports.^[@ref12]^ All SapB solutions in this study were prepared in 50 mM phosphate buffer, pH 5.5. Protein concentration was determined spectrophotometrically using a molar absorptivity value of 2950 M^--1^ cm^--1^ at 280 nm. Ligand solutions were prepared in 100% dimethylformamide (DMF) to a concentration of 2 mM, with the exception of hydoxychloroquine (HCQ), which was prepared in 50 mM phosphate buffer, pH 5.5. The concentrations of all the ligands were determined via ultraviolet--visible spectroscopy using molar absorptivity values of: 36 900 M^--1^ cm^--1^ at 440 nm for A2E; 7500 M^--1^ cm^--1^ at 331 nm for CQ; 226.9 M^--1^ cm^--1^ at 329 for HCQ; 27 300 M^--1^ cm^--1^ at 253 nm for ATO; 22 540 M^--1^ cm^--1^ at 279 nm for PEth; 27 500 M^--1^ cm^--1^ at 280 nm for PCho; 4150 M^--1^ cm^--1^ at 283 for CoQ~4~; and 3750 M^--1^ cm^--1^ at 282 nm for CoQ~9~.

4.2. Fluorescence Spectroscopy {#sec4.2}
------------------------------

Fluorescence quenching measurements were performed on a Varian Cary Eclipse fluorimeter equipped with a QNW Peltier temperature controller. The binding experiments were conducted at 25.00 ± 0.01 °C in 50 mM phosphate buffer, pH 5.5, using 278 nm excitation wavelength for SapB emission spectra at 330 nm ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a--f) with excitation and emission monochromators bandwidth of 5 nm each. Temperature sensitive binding experiments were performed between 20.00 ± 0.01 and 40.00 ± 0.01 °C using 278 nm excitation wavelength for SapB emission spectra at 331 nm, with excitation and emission monochromators bandwidth of 5 nm each. The fluorescence quenching data were analyzed using OriginLab software version 8.

4.3. Docking Studies {#sec4.3}
--------------------

Studies were performed with SwissDock using the structure of SapB-CQ (PDB 4V2O) as a model. The orientation of the ATO ligand was checked manually using Coot and optimized for putative hydrogen bonding interactions.^[@ref21]−[@ref23]^

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.7b01334](http://pubs.acs.org/doi/abs/10.1021/acsomega.7b01334).Detailed experimental descriptions, van't Hoff plots, Stern--Volmer plots, spectrophotometric titration plots ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01334/suppl_file/ao7b01334_si_001.pdf))
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